Maybank’s Buy Call Puts LACMED Upside at 60% as Hospital Expansion Supports Growth

C.R. Lee ·

AI-assisted, reviewed by C.R. Lee

Maybank Investment Bank analyst Aseela Zahari initiated coverage of LAC Med with a “Buy” rating and RM1.15 target price, implying approximately 60% upside. She views the medical equipment distributor and systems integrator as a beneficiary of Malaysia’s hospital expansion, equipment replacement demand and growing higher-margin recurring services.

​

The group serves 217 Malaysian hospitals, representing approximately 58% of the market. Equipment replacement demand historically accounted for around 75% of revenue, with replacement cycles typically spanning seven to 12 years. A planned addition of approximately 4,800 private hospital beds also presents opportunities for equipment supply and integration work.

​

Aseela forecasts core net profit to reach RM40.4 million in 2028, representing approximately 21.3% annualised growth from 2025. Maintenance, equipment leasing and medical imaging software could support management’s target to increase recurring revenue from approximately 20% in 1H26 to 40% within five years.

​

As of 9:50 a.m. on November 17, LAC Med’s share price fell 4.0% to RM0.72.

​

Disclaimer: All content is AI-aggregated from public sources for informational and educational purposes only. StockTipRatings.com does not constitute investment advice. Past performance and historical statistics are no guarantee of future returns.

​

The call: Maybank on LAC MED BERHAD

Rating
Buy
Target price
RM 1.15
Upside from current
55.4%

Aseela Zahari's 12-month track record

Success rate
100%
Average return
52%
Stocks covered
4

Aseela Zahari's profile · Unlock past LACMED calls

Consensus target price for LACMED

Sign up free to see the consensus target, or read the LACMED target price and analyst ratings.

Stocks in this article

Experts in this article

Broker

Sector: Healthcare

More on LACMED

More Bursa Malaysia analyst news · Top-rated Malaysian stock analysts